119 related articles for article (PubMed ID: 7983231)
1. Genetic differences in drug disposition.
May DG
J Clin Pharmacol; 1994 Sep; 34(9):881-97. PubMed ID: 7983231
[TBL] [Abstract][Full Text] [Related]
2. [Genetic polymorphisms of drug metabolizing enzymes].
Fujieda M; Yamazaki H; Kamataki T
Gan To Kagaku Ryoho; 2002 May; 29(5):663-8. PubMed ID: 12040668
[TBL] [Abstract][Full Text] [Related]
3. [Status of pharmacogenomics and its future role in drug therapy].
Cascorbi I
Internist (Berl); 2002 Apr; 43(4):506-10. PubMed ID: 12053407
[No Abstract] [Full Text] [Related]
4. [Individualization of drug therapy and pharmacogenetics].
Yamamoto I; Azuma J
Nihon Rinsho; 1998 Mar; 56(3):579-83. PubMed ID: 9549339
[TBL] [Abstract][Full Text] [Related]
5. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer.
Nebert DW; McKinnon RA; Puga A
DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263
[TBL] [Abstract][Full Text] [Related]
6. [Interindividual differences in efficacy and toxicity induced by therapeutic drugs and xenobiotics in relation to genetic polymorphisms in xenobiotic metabolizing enzymes].
Ozawa S
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1998; (116):69-81. PubMed ID: 10097514
[TBL] [Abstract][Full Text] [Related]
7. CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.
Miners J
Pharmacogenetics; 2002 Mar; 12(2):91-2. PubMed ID: 11875362
[No Abstract] [Full Text] [Related]
8. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
[TBL] [Abstract][Full Text] [Related]
9. Identification of human CYP2C19 residues that confer S-mephenytoin 4'-hydroxylation activity to CYP2C9.
Tsao CC; Wester MR; Ghanayem B; Coulter SJ; Chanas B; Johnson EF; Goldstein JA
Biochemistry; 2001 Feb; 40(7):1937-44. PubMed ID: 11329260
[TBL] [Abstract][Full Text] [Related]
10. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
Frye RF; Branch RA
Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
[TBL] [Abstract][Full Text] [Related]
11. Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis.
Borlak J; Thum T
Clin Chem; 2002 Sep; 48(9):1592-4. PubMed ID: 12194942
[No Abstract] [Full Text] [Related]
12. Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans.
Funck-Brentano C; Bosco O; Jacqz-Aigrain E; Keundjian A; Jaillon P
Clin Pharmacol Ther; 1992 May; 51(5):507-12. PubMed ID: 1587064
[TBL] [Abstract][Full Text] [Related]
13. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms.
Nielsen KK; Brøsen K; Hansen MG; Gram LF
Clin Pharmacol Ther; 1994 May; 55(5):518-27. PubMed ID: 8181196
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of CYP2C subfamily in a Japanese population.
Ieiri I; Higuchi S
J Toxicol Sci; 1998 Jul; 23 Suppl 2():129-31. PubMed ID: 9760448
[No Abstract] [Full Text] [Related]
15. Phenotyping of drug metabolism in infants and children: potentials and problems.
Rane A
Pediatrics; 1999 Sep; 104(3 Pt 2):640-3. PubMed ID: 10469807
[No Abstract] [Full Text] [Related]
16. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
[TBL] [Abstract][Full Text] [Related]
17. Populations and genetic polymorphisms.
Weber WW
Mol Diagn; 1999 Dec; 4(4):299-307. PubMed ID: 10671640
[TBL] [Abstract][Full Text] [Related]
18. [Genetic polymorphism in Gilbert-Meulengracht syndrome (GMS)].
Fengler JD; Baumgarten R; Eike E; Eike O; Siegmund W; Franke G; Zschiesche M
Z Gastroenterol; 1993 Feb; 31 Suppl 2():81-2. PubMed ID: 7483725
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro.
Störmer E; Brockmöller J; Roots I; Schmider J
Psychopharmacology (Berl); 2000 Sep; 151(4):312-20. PubMed ID: 11026737
[TBL] [Abstract][Full Text] [Related]
20. Adverse drug reaction monitoring in Jena. Relevance of polymorphic drug metabolizing enzymes for inducing adverse drug reactions.
Hippius M; Buchardt C; Farker K; Kuhn UD; Reimann IR; Hoffmann A
Exp Toxicol Pathol; 2003 Jun; 54(5-6):417-21. PubMed ID: 12877354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
